España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Benzinga Pro
Data & APIs
Events
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Johnson & Johnson
JNJ
NYSE
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$144.47
0.89
0.62%
At close: -
$144.70
0.23
0.16%
After Hours: 6:27 PM EDT
Get Report
Comment
Johnson & Johnson (JNJ) Forecast
News
Earnings
Johnson & Johnson (JNJ) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Government Trades
Short Interest
Latest news for Johnson & Johnson (NYSE:JNJ) Stock
Johnson & Johnson Stock (NYSE: JNJ)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Thursday, December 19, 2024
Your Healthcare Costs are Soaring! US Spending Reached $5 Trillion In 2023 with Major Increase in Obesity and Diabetes Drugs, Hospital Services
Vandana Singh
Tuesday, December 17, 2024
FDA Rejects Johnson & Johnson's Injectable Version Of Approved Drug For Lung Cancer
Vandana Singh
Friday, December 13, 2024
"J&J Accuses Big Health Insurer of Helping Dr...
Benzinga Newsdesk
Johnson & Johnson Options Trading: A Deep Dive into Market Sentiment
Benzinga Insights
Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report
Vandana Singh
Thursday, December 12, 2024
Jim Cramer Says This CEO 'Built An Amazing Company,' Recommends Buying Netflix
Avi Kapoor
Jim Cramer Bullish On Netflix Nearing $1,000 And AMD's 'Cheap' Valuation Despite Nvidia Dominance
Kaustubh Bagalkote
Wednesday, December 11, 2024
Citigroup Maintains Buy on Johnson & Johnson,...
Benzinga Newsdesk
Tuesday, December 10, 2024
GSK's Blood Cancer Drug Shows Improved Survival Compared To Johnson & Johnson's Darzalex
Vandana Singh
10 Health Care Stocks With Whale Alerts In Today's Session
Benzinga Insights
The Analyst Landscape: 15 Takes On Johnson & Johnson
Benzinga Insights
B of A Securities Reinstates Neutral on Johns...
Benzinga Newsdesk
Monday, December 09, 2024
Reported Sunday, Johnson & Johnson Highlights...
Benzinga Newsdesk
Sunday, December 08, 2024
Johnson & Johnson Announced Darzalex Faspro S...
Benzinga Newsdesk
Thursday, December 05, 2024
10 Health Care Stocks Whale Activity In Today's Session
Benzinga Insights
Tuesday, December 03, 2024
Ray Dalio's Bridgewater Adds Broadcom, Apple, SMCI In Q3, While Offloading Stake In AI Giant Nvidia And Other Big Tech Companies
Rishabh Mishra
Monday, December 02, 2024
Johnson & Johnson Has Submitted Two Supplemen...
Benzinga Newsdesk
Friday, November 29, 2024
Bristol-Myers Squibb Files Lawsuit Against US Agency For Overreach In 340B Drug Pricing Program
Vandana Singh
Friday, November 22, 2024
Johnson & Johnson Submits Supplemental Biolog...
Benzinga Newsdesk
Thursday, November 21, 2024
Johnson & Johnson Announces Health Canada Aut...
Benzinga Newsdesk
Spotlight on Johnson & Johnson: Analyzing the Surge in Options Activity
Benzinga Insights
Price Over Earnings Overview: Johnson & Johnson
Benzinga Insights
Wednesday, November 20, 2024
U.S. CDC Says Flu, Covid-19, RSV Illnesses Ar...
Benzinga Newsdesk
Reported Earlier, "J&J, Merck Cut Jobs in Chi...
Benzinga Newsdesk
Monday, November 18, 2024
Johnson & Johnson Announced Topline Results F...
Benzinga Newsdesk
Friday, November 15, 2024
This Is What Whales Are Betting On Johnson & Johnson
Benzinga Insights
CHMP Recommends Approval Of Janssen's Rybreva...
Benzinga Newsdesk
This Johnson & Johnson Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Avi Kapoor
Wolfe Research Initiates Coverage On Johnson ...
Benzinga Newsdesk
Thursday, November 14, 2024
Trump Taps RFK Jr. For Health Secretary Role, Sends 5 Vaccine Stocks Lower
Michael Cohen
Johnson & Johnson's Nipocalimab Achieves Over...
Benzinga Newsdesk
Johnson & Johnson MedTech Announces Exclusive...
Benzinga Newsdesk
Wednesday, November 13, 2024
Johnson & Johnson Challenges Government Drug Pricing Dispute Over Two Drugs
Vandana Singh
Monday, November 11, 2024
Johnson & Johnson Today Announces That The U....
Benzinga Newsdesk
Friday, November 08, 2024
Johnson & Johnson Submits Regulatory Applicat...
Benzinga Newsdesk
Thursday, November 07, 2024
Industry Comparison: Evaluating Johnson & Johnson Against Competitors In Pharmaceuticals Industry
Benzinga Insights
Wednesday, November 06, 2024
Guggenheim Maintains Neutral on Johnson & Joh...
Benzinga Newsdesk
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 3% Dividend Yields
Avi Kapoor
Monday, October 28, 2024
Global Psychedelic Drugs Market Expected To Reach $10.2B By 2028 Amid Growing Mental Health Crises
Juan Spínelli
Google To Launch New "Sexual Health & Wellnes...
Benzinga Newsdesk
Johnson & Johnson's Tremfya Seeks Expanded Use Approval After It Shares Encouraging Late-Stage Study Data In Crohn's Disease
Vandana Singh
Johnson & Johnson Announced Results From Phas...
Benzinga Newsdesk
Friday, October 25, 2024
Johnson & Johnson's Blockbuster Drug Tremfya Clears Plaque Psoriasis With Lesions Covering Body's Smaller Areas
Vandana Singh
Johnson & Johnson's SPECTREM Study Shows TREM...
Benzinga Newsdesk
Thursday, October 24, 2024
Comparative Study: Johnson & Johnson And Industry Competitors In Pharmaceuticals Industry
Benzinga Insights
Wednesday, October 23, 2024
DARZALEX-SC Based Quadruplet Regimen Approved...
Benzinga Newsdesk
Tuesday, October 22, 2024
Justice Department's Trustee Program Alleges Johnson & Johnson's Talc Litigation Bankruptcy Bid Is Bad-Faith Tactic To Avoid Liability
Vandana Singh
Peering Into Johnson & Johnson's Recent Short Interest
Benzinga Insights
Monday, October 21, 2024
What's Going On With Kenvue Stock Monday?
Dylan Berman
Tylenol, Listerine Maker Kenvue Under Activist Spotlight With Starboard Value Stake — Overhaul Ahead For The Johnson & Johnson Spinoff?
Benzinga Neuro
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch